The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Sima Singh; Arshid Numan; Balaji Maddiboyina; Saahil Arora; Yassine Riadi; Shadab Md; Nabil A Alhakamy; Prashant Kesharwani

doi:10.1016/j.drudis.2021.03.011

The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer

Drug Discov Today. 2021 Jul;26(7):1721-1727. doi: 10.1016/j.drudis.2021.03.011. Epub 2021 Mar 18.

Authors

Sima Singh¹, Arshid Numan², Balaji Maddiboyina³, Saahil Arora⁴, Yassine Riadi⁵, Shadab Md⁶, Nabil A Alhakamy⁶, Prashant Kesharwani⁷

Affiliations

¹ University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab 140413, India.
² State Key Laboratory of ASIC and System, SIST, Fudan University, 200433 Shanghai, China.
³ Department of Pharmacy, NRK & KSR Gupta College of Pharmacy, Tenali, Guntur, 522202 AP, India.
⁴ University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab 140413, India. Electronic address: director.uips@cumail.in.
⁵ Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
⁶ Deptartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Center of Excellence for Drug Research & Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
⁷ Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address: prashantdops@gmail.com.

PMID: 33745879
DOI: 10.1016/j.drudis.2021.03.011

Abstract

Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss future opportunities for their use in TNBC.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Humans
Immune Checkpoint Inhibitors / therapeutic use*
Immunotherapy
Triple Negative Breast Neoplasms / therapy*
Tumor Microenvironment

Substances

Immune Checkpoint Inhibitors